Latest Hyperphosphatemia News
In a meta-analysis, hemodialysis patients using lanthanum carbonate to lower phosphorus levels had a 55% decreased risk of death compared with those taking other binders.
A serum phosphate control target of 4.5 mg/dL or below in hemodialysis patients was accompanied by a decline in fibroblast growth factor 23.
Mean 25-hydroxyvitamin D levels did not differ significantly among groups receiving phosphate binders or dietary therapy.
In a study, intact parathyroid hormone levels fell by nearly 10% over 6 months in hemodialysis patients who received intensive treatment for hyperphosphatemia.
Excess calcium following a meal may be deposited in soft tissue and blood vessels, researchers hypothesize.
Sucroferric oxyhydroxide and sevelemer are similarly effective in lower phosphorus levels in dialysis patients, but the former is associated with less toxicity and lower pill burden.
In addition, average phosphate binder pill burden decreased by more than half.
Panel focuses on diagnosing and testing of CKD-MBD and treatment of the CKD-MBD that emphasizes decreasing phosphate, maintaining calcium, and addressing elevated PTH in adults with CKD stage G3a to G5.
Abnormal calcium-phosphate metabolism appears to be an important pathogenic factor in the development of vascular calcification in patients with chronic kidney disease.
Additives in packaged meat, poultry, and fish can contribute significantly to the dietary phosphorus and potassium loads in CKD patients, researchers say.
The use of phosphate binders to manage hyperphosphatemia in maintenance hemodialysis patients might allow diets less restricted in protein and calories, according to a study.
Serum phosphorus fell to similar levels in two-thirds of peritoneal dialysis patients, but sucroferric oxyhdroxide recipients had a lower pill burden.
In a study of patients with chronic kidney disease and cardiovascular disease, niacin therapy lowered serum phosphate by just 0.25 mg/dL over 3 years compared with placebo.
Phosphate binder use is associated with a 25% and 37% decreased risk of death from infection-related causes and all-causes, respectively, compared with non-users.
Achieving a phosphate value of 1.4 mmol/L seemed optimal.
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)